Ono Pharmaceutical Co., Ltd.: Business Overview, Financials & Competitive Analysis
Ono Pharmaceutical Co., Ltd. scores 6/10 on the AskCyborg Cyborg Score (Solid). Established Japanese pharma with solid oncology exposure but facing revenue headwinds and premium valuation require careful assessment. Recent results show sales and net income above prior year, with P/E at 19.1x, slightly expensive versus peers at 15.4x. However, risks exist including annual revenue and net income contraction, indicating.
What is Ono Pharmaceutical Co., Ltd.'s industry? Ono Pharmaceutical Co., Ltd. (ono-pharma.com) operates in Pharmaceuticals & Healthcare. AskCyborg classifies Ono Pharmaceutical Co., Ltd. under Pharmaceuticals & Healthcare in its company registry.
Ono Pharmaceutical is one of the largest pharmaceutical companies in Japan, with a diversified portfolio spanning oncology, cardiovascular, respiratory, and metabolic diseases. The company offers flagship products inc...
Cyborg Score thesis
Established Japanese pharma with solid oncology exposure but facing revenue headwinds and premium valuation require careful...
Read the full analyst-debate transcript →Get the Latest Ono Pharmaceutical Co., Ltd. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeOno Pharmaceutical Co., Ltd. Overview
Pro stress-test →Ono Pharmaceutical is one of the largest pharmaceutical companies in Japan, with a diversified portfolio spanning oncology, cardiovascular, respiratory, and metabolic diseases. The company offers flagship products including Opdivo for malignant tumors and Kyprolis for cancer treatment, positioning itself as a meaningful player in global pharmaceutical markets.
Strategic Profile
Pro stress-test →Ono Pharmaceutical is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. The bulk of the company's sales is generated in Japan, followed by the rest of Asia and Europe, with a balanced pipeline across multiple therapeutic areas rather than dependence on single blockbuster drugs.
Competitive Landscape
Pro stress-test →Ono's portfolio includes medicines for type II diabetes, overactive bladder, osteoporosis, cancer, chemotherapy-induced nausea and vomiting, Alzheimer's disease, and respiratory conditions. The company competes against major global pharma firms in oncology (particularly with Opdivo) and regional players in traditional therapeutic areas, with competitive positioning strengthened by established product franchises in circulatory and respiratory segments.
Industry Context
Ono Pharmaceutical Co., Ltd. operates in Pharmaceuticals & Healthcare.
Key facts
Founded: 1717 · Headquarters: Osaka, Japan · Employees: 4,287 · Revenue: $3.4B · Market cap: $7.7B